Latest Conference Articles

John J. Chen, MD, PhD, of Mayo Clinic discusses how NMOSD and MOGAD antibodies are changing optic neuritis care and the two trials now enrolling.

Twice-daily clobetasol 0.05% cleared cells in 26.5% vs 8.6% of patients and pain in 75.1% vs 32.4% after cataract surgery, with no added endothelial cell loss.

Initial phaco for angle-closure glaucoma climbed to 48.4% in adults 50 and older, while surveys and IRIS data show shifting trabeculectomy and JOAG surgical patterns.

Liangbo Linus Shen, MD, shared phase 2 data showing kamuvudine K8 reduced geographic atrophy growth by 54%.

A cataract expert discussed if postoperative topical antibiotics add protection after intracameral prophylaxis.

Donald J. D’Amico, MD, presents 1-year pivotal results comparing a Wnt pathway agonist with ranibizumab in diabetic macular edema.

Mark J. Gallardo, MD, discusses how the laser performed alongside cataract surgery in open-angle glaucoma, including medication burden and safety.

Oral PKC inhibitor darovasertib preserved the eye in 57% of patients facing enucleation and cut projected radiation doses in 70.3% in the phase 2 OptimUM-09 trial.

Drew Carey, MD, and Andrew G. Lee, MD, discuss triage, visual fields, double vision, and cataract topics from Neuro-Ophthalmology Subspecialty Day.

At AAO 2026 Retina Subspecialty Day, SriniVas Sadda, MD, outlined limits of current GA growth metrics and introduced border advancement pace and a location-weighted GA severity score.

At EURETINA 2026, Mitrofanis Pavlidis, MD, PhD, explains how double-cutting probes, new pump technology and integrated visualisation reduced core vitrectomy time in 27-gauge surgery.

At EURETINA 2026, Paola Sasso, MD, and Antonio Baldascino, MD, discussed cataract surgery with the EyeMax Mono IOL followed by structured visual rehabilitation in patients with late-stage AMD.

Tunde Peto, MD, PhD, explains how ultra-widefield imaging showed that macular degeneration affects the peripheral retina, and why measuring both peripheral and central vision matters for patients’ daily function.

At the American Academy of Ophthalmology (AAO) 2026 Retina Subspecialty Day in New Orleans, Charles C. Wykoff, MD, PhD, presented 1-year primary end point results from the phase 3 DAYBREAK trial.

A glaucoma expert addressed the connection between systemic blood pressure, intraocular pressure, and glaucoma.

Michel Michaelides, MD, discusses phase 3 DRAGON results showing that oral tinlarebant slowed atrophic lesion growth by about 36% in adolescents with Stargardt disease.

A single intravitreal injection improved acuity in Stargardt disease; a randomized trial in geographic atrophy is planned.

At EURETINA 2026, Jordi Monés, MD, PhD, outlined the rationale for gene-agnostic optogenetic therapy MCO-010 to restore vision in Stargardt disease and geographic atrophy.

September was one of the busiest months of the year in eye care—From ESCRS to Eyecon

Real-world VOYAGER data at EURETINA 2026 show vision and anatomic outcomes with faricimab across nAMD, DME, and RVO.

At EURETINA 2026, David Steel reviewed registry evidence on gas and silicone oil tamponades for retinal detachment repair and outlined novel tamponade agents in his Kreissig Award Lecture.

Sunir Garg, MD, FACS, previews DME and dry AMD data, free papers, and surgical sessions at AAO 2026.

Cataract original papers on intracameral antibiotics and IOL power, a guideline-based case symposium, and ocular surface sessions headline AAO 2026.

Ritesh Narula, MBBS, MS, discusses phase 1 and early phase 2 results of the Eyestem subretinal stem cell study in geographic atrophy, including an 11-letter mean visual acuity gain maintained at 18 months.

At EURETINA 2026, Arshad Khanani, MD, FASRS, reviews sura-vec, 4D-150 and ixo-vec, 3 nAMD gene therapies in phase 3 with readouts expected over the next 12 months.

Ashish Sharma, MD, on what real-world data show about switching and long-term outcomes with retinal biosimilars.

João Pedro Marques, MD, MSc, PhD, FEBOphth, discusses the IRD-PT, a web-based Portuguese registry of roughly 2,400 patients with inherited retinal diseases that supports research and identifies patients for clinical trials.

At EURETINA 2026, Elon van Dijk, MD, PhD, FEBOphth, reviewed trial evidence favouring half-dose PDT over micropulse laser and eplerenone for central serous chorioretinopathy.